Core Viewpoint - The company Gan Zhicao is preparing for an IPO, having established itself as a leader in China's online traditional Chinese medicine (TCM) sector, but faces challenges with high growth and low profitability [1][5]. Group 1: Company Overview - Gan Zhicao was founded in 2015, inspired by a moment when a co-founder had to write a prescription on a napkin, leading to the idea of integrating TCM with the internet [2]. - The company holds a 4.9% market share in the online TCM comprehensive service market and a 16.7% share in the online TCM diagnosis service segment, significantly outpacing its competitors [2][4]. - The business model leverages digital tools to streamline the entire process from diagnosis to medication and daily health maintenance, serving both patients and small TCM clinics [3]. Group 2: Financial Performance - Revenue is projected to grow from 603 million yuan in 2023 to 690 million yuan in 2024, with 555 million yuan achieved in the first nine months of 2025 [4]. - Despite revenue growth, the company reported a net loss of 123.5 million yuan in the first nine months of 2025, primarily due to increased sales and distribution expenses [6][7]. - The gross profit margin for online TCM diagnosis services is between 22% and 24%, while offline services have a lower margin of 6.7% to 13.4% [6]. Group 3: Market Context - The online TCM comprehensive service market in China has expanded dramatically from 2.7 billion yuan in 2019 to an estimated 13 billion yuan in 2024 [5]. - The company's revenue structure is diversifying, with the share of online TCM diagnosis services decreasing from 85.3% to 70.1%, while SaaS and consumer health products are gaining ground [6]. Group 4: Capital and Governance - Gan Zhicao has seen a significant increase in valuation, rising from under 7 million yuan in early 2023 to over 1.6 billion yuan, a 240-fold increase [8][9]. - The company has engaged in multiple capital operations, including share transfers and investments from various institutions, raising concerns about governance and related party transactions [9][10]. - The company has not yet secured professional medical liability insurance for its online TCM services, which poses potential risks [7].

Group 1 - The core viewpoint of the article is that Hangzhou Gan Zhicao Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to capitalize on its leading position in the online traditional Chinese medicine (TCM) service market [1] - According to a report by Frost & Sullivan, the top five online TCM service providers in China hold a combined market share of 10.7% based on projected 2024 revenue, with Gan Zhicao leading at 4.9% [1] - Gan Zhicao also ranks first in the online TCM diagnosis service market with a market share of 16.7% based on projected 2024 revenue, indicating its dominance in this key segment [1] Group 2 - The company is described as a leading online TCM service provider driven by digital intelligence, focusing on online TCM diagnosis services and expanding into a full industry chain that includes TCM diagnosis, medical institution services, and health products [3]